The Metabolic Remodelling in Lung Cancer and Its Putative Consequence in Therapy Response
- 210 Downloads
Lung cancer is the leading cause of cancer-related deaths worldwide in both men and women. Conventional chemotherapy has failed to provide long-term benefits for many patients and in the past decade, important advances were made to understand the underlying molecular/genetic mechanisms of lung cancer, allowing the unfolding of several other pathological entities. Considering these molecular subtypes, and the appearance of promising targeted therapies, an effective personalized control of the disease has emerged, nonetheless benefiting a small proportion of patients. Although immunotherapy has also appeared as a new hope, it is still not accessible to the majority of patients with lung cancer.
The metabolism of energy and biomass is the basis of cellular survival. This is true for normal cells under physiological conditions and it is also true for pathophysiologically altered cells, such as cancer cells. Thus, knowledge of the metabolic remodelling that occurs in cancer cells in the sense of, on one hand, surviving in the microenvironment of the organ in which the tumour develops and, on the other hand, escaping from drugs conditioned microenvironment, is essential to understand the disease and to develop new therapeutic approaches.
KeywordsMetabolic remodelling Tumor microenvironment Lung cancer Targeted therapy New therapeutic approaches
The authors acknowledge iNOVA4Health – UID/Multi/04462/2013, a program financially supported by Fundação para a Ciência e Tecnologia/Ministério da Educação e Ciência, through national funds and co-funded by FEDER under the PT2020 Partnership Agreement.
- Achek A, Kwon H, Lee B, Yoo TH (2017) TLR4/MD2 specific peptides stalled in vivo LPS-induced immune exacerbation. Biomaterials 126:49–60. https://doi.org/10.1016/j.biomaterials.2017.02.023CrossRefPubMedGoogle Scholar
- Chen P-H, Cai L, Kim HS et al (2014b) Metabolic diversity in human non-small cell lung cancer. Cancer Metab 2. https://doi.org/10.1186/2049-3002-2-s1-p13
- Ciamporcero E, Daga M, Pizzimenti S et al (2018) Crosstalk between Nrf2 and YAP contributes to maintaining the antioxidant potential and chemoresistance in bladder cancer. Free Radic Biol Med 115:447–457. https://doi.org/10.1016/j.freeradbiomed.2017.12.005CrossRefPubMedGoogle Scholar
- Cruz-Bermúdez A, Laza-Briviesca R, Vicente-Blanco RJ et al (2019) Cancer-associated fibroblasts modify lung cancer metabolism involving ROS and TGF-β signaling. Free Radic Biol Med 130:163–173. https://doi.org/10.1016/j.freeradbiomed.2018.10.450CrossRefPubMedGoogle Scholar
- Dranka BP, Hill BG, Darley-Usmar VM (2010) Mitochondrial reserve capacity in endothelial cells: the impact of nitric oxide and reactive oxygen species. Free Radic Biol Med 48:905–914. https://doi.org/10.1016/j.freeradbiomed.2010.01.015CrossRefPubMedPubMedCentralGoogle Scholar
- I H, Cho J-Y (2015) Lung. Cancer Biomark:107–170Google Scholar
- Inamura K (2017) Lung cancer: understanding its molecular pathology and the 2015 WHO classification. Front Oncol 7. https://doi.org/10.3389/fonc.2017.00193
- Lopes-Coelho F, Gouveia-Fernandes S, Nunes SC, Serpa J (2017) Metabolic dynamics in breast cancer: cooperation between cancer and stromal breast cancer cells. J Clin Breast Cancer Res 1:1–7Google Scholar
- Mallappa S, Neeli PK, Karnewar S, Kotamraju S (2019) Doxorubicin induces prostate cancer drug resistance by upregulation of ABCG4 through GSH depletion and CREB activation: relevance of statins in chemosensitization. Mol Carcinog 58:1118–1133. https://doi.org/10.1002/mc.22996CrossRefPubMedGoogle Scholar
- Tran S, Ready N, Krug LM, Pietanza MC, Jungbluth AA, Pan LS, Venhaus RR, Hoffman EW, Peters A-M, Dukelow K, Bomalaski JS, Wu B-W, LJO (2012) Phase II study of ADI-PEG 20 in patients with relapsed sensitive or refractory small cell lung cancer. J Clin Oncol 30:e17558–e17558Google Scholar
- Ying L, Zhu Z, Xu Z et al (2015) Cancer associated fibroblast-derived hepatocyte growth factor inhibits the paclitaxel-induced apoptosis of lung cancer A549 cells by up-regulating the PI3K/Akt and GRP78 signaling on a microfluidic platform. PLoS One 10:e0129593. https://doi.org/10.1371/journal.pone.0129593CrossRefPubMedPubMedCentralGoogle Scholar
- Zimmer AD, Walbrecq G, Kozar I et al (2016) Phosphorylation of the pyruvate dehydrogenase complex precedes HIF-1-mediated effects and pyruvate dehydrogenase kinase 1 upregulation during the first hours of hypoxic treatment in hepatocellular carcinoma cells. Hypoxia 4:135–145. https://doi.org/10.2147/HP.S99044CrossRefPubMedPubMedCentralGoogle Scholar